• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
45 results

TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS...

Docket 16/306,305, U.S. Patent Application (Nov. 30, 2018)
Art Group1627
Case TypeUtility - 514/230500
Class514
Inventor Michele HUMMEL
Inventor Donald J. KYLE
Inventor Laykea TAFESSE
...
cite Cite Docket
Analyze

Response to Election / Restriction Filed

Document TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT, 16/306,305, No. 1-3-US-163063050QP1 (U.S. Pat. App. Mar. 2, 2020)
This compound can be prepared by methods known in the art as described in paragraph [0093] of the specification as originally filed.
Application No. 16/306,305 (S)-N-(4-(2-(2-amino-4,5-dihydrooxazol-4-yl)ethyl)phenyl)-4-chlorobenzamide has been screened in a hTAARl functional assay and the EC50 and Emax values obtained for this compound are described in Example 15, in the first entry of Table 1 at paragraph [0172], of the specification as originally filed.
This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.
It is not believed that extensions of time are required beyond those that may otherwise be provided for in documents accompanying this paper.
However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any additional fees required to continue prosecution or appeal of this application (including issue fee, fees for net addition of claims or PPLP Ref: 15-NC-0004USO3 Atty.
cite Cite Document
Analyze

Foreign Reference

Document TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT, 16/306,305, No. 341-85-US-163063050SP1 (U.S. Pat. App. Apr. 14, 2020)
[0028] The present disclosure further provides a method of treating or ameliorating chronic pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound described herein.
PCT/USZOl7/031071 _ 12 _ well as their racemic and resolved forms and mixtures thereof Further, individual diastereomers and enantiomers of a compound of the invention may be separated according to methods known to those of ordinary skill in the art in view of the present disclosure.
[0048] In some embodiments, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Y1 and Y2 are each independently phenyl, naphthyl, thiophenyl, pyridinyl, cycloalkyl, 1,2,3,4-tetrahydro- naphthalen-Z-yl, 2,3-dihydrobenzo[l,4]dioxin-6-yl, or benzo[l,3]dioxol-5-yl.
[0056] In some embodiments, the present disclosure provides a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, wherein Y1 is phenyl, naphthyl, thiophenyl, pyndinyl, cycloalkyl, l,2,3,4-tetrahydro-naphthalen-Z-yl, 2,3- dihydrobenzo[1,4]dioxin-6-yl, or benzo[I,3]dioxol-5-yl.
It is within the common knowledge of a synthetic and/or medicinal chemist to construct compounds of the present disclosure by utilizing two oxazoline moieties as above described with the same of different steric configurations.
cite Cite Document
Analyze

Information Disclosure Statement (IDS) Form (SB08)

Document TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT, 16/306,305, No. 1-1-US-163063050RP1 (U.S. Pat. App. Apr. 14, 2020)
Examiner initials" Cite _ocumentNumber Number—Kind Code 2 (If Pages, Columns, Lines, Where Relevant Passages orRelevant Figures Appear known) Publication Date
2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
5 Applicant is to place a check mark here if English language Translation is attached.
cite Cite Document
Analyze

Transmittal Letter

Document TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT, 16/306,305, No. 537-3-US-163063050SP1 (U.S. Pat. App. Apr. 14, 2020)
Art Unit: 1627 Application No.: 16/3 06,3 05 Examiner: KANTAMNENI, SHOBHA 371(c) Date: November 30, 2018 Atty.
Applicant has listed publication dates on the attached IDS Forms based on information presently available to the undersigned.
This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.
It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.
Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.
cite Cite Document
Analyze

1-1-US-163063050SP1

Document TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT, 16/306,305, No. 1-1-US-163063050SP1 (U.S. Pat. App. Apr. 14, 2020)

cite Cite Document
Analyze

2-168-US-163063050SP1

Document TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT, 16/306,305, No. 2-168-US-163063050SP1 (U.S. Pat. App. Apr. 14, 2020)

cite Cite Document
Analyze

533-4-US-163063050SP1

Document TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT, 16/306,305, No. 533-4-US-163063050SP1 (U.S. Pat. App. Apr. 14, 2020)

cite Cite Document
Analyze
1 2 3 4 >>